Skip to main content
Clinical Trials/NCT04190121
NCT04190121
Unknown
Not Applicable

Perioperative Nutritional Support in Esophageal Cancer Patients

THEODOROU DIMITRIOS1 site in 1 country110 target enrollmentMarch 26, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Esophageal Cancer
Sponsor
THEODOROU DIMITRIOS
Enrollment
110
Locations
1
Primary Endpoint
infective complications
Last Updated
6 years ago

Overview

Brief Summary

Upper GI malignancies often lead to involuntary weight loss and nutritional deficits. Nutritional support, both pre- and postoperatively, may improve post-operative course and reduce length of hospital stay. This prospective randomized trial aims to investigate the above mentioned hypothesis and clarify any variants that may differ between the investigation and control group at a statistically significant level.

Detailed Description

This prospective randomized trial is conducted in the 1st Propaedeutic Department of Surgery of National and Kapodistrian University of Athens. The study population consists of adults suffering from upper GI malignancy. Informed consent is obtained in written. Following this, the patient is classified in either the intervention group or the control group. Patients belonging in the control group will receive the usual postoperative care, while the patients in the intervention group will receive nutritional support perioperatively. The aforementioned "usual postoperative care" consists of administration of intravenous fluids until resuming oral feeding, jejunostomy feeding starting from the first postoperative day, epidural analgesics for the first four postoperative days, perioperative administration of a second generation cephalosporin plus metronidazole and thromboprophylaxis with (low moleculr weight heparin (LMWH). The patients are also receiving appropriate for any concomitant health problems (e.g. existing diabetes mellitus) and transfusions based on their needs. We record the patient's age, the stage and histologic type of the disease, administration of adjuvant and/or neoadjuvant therapy and the patient's American Society of Anesthesiologists Score. Their preoperative nutritional state will be assessed using Body Mass Index (BMI), serum albumin, body fat percentage, muscle mass and total body water following measurement with body composition analyzer (Tanita MC-780U Multi Frequency Segmental Body Composition Analyzer). At their initial assessment the patients will fill in an appropriate quality of life questionnaire. The type of the operation, the use of drains and catheters, the patients needs in iv fluids, blood product transfusions, sedatives and analgesics during the operation will also be recorded. The postoperative course of any patient will be closely monitored, including the postoperative needs in fluid administration and analgesics, the need for transfusion, the administration of perioperative antibiotics, the removal of drains and catheters, the time of first bowel movement,the need of ICU hospitalization, the total length of hospital stay as well as any in-hospital complications. Upon discharge from the hospital, the control group will receive instructions on oral and jejunostomy feeding, while the intervention group will receive additional nutritional support for 3 months. Both patient groups will undergo post-operative follow-up for six months. In the first, third and sixth postoperative month body weight and its change, BMI, serum albumin, body fat percentage, muscle mass and total body water, as well as quality of life, postoperative complications and need for readmission will be evaluated. Neoadjuvant therapy will also be taken into account. The results will be statistically evaluated after appropriate stratification.

Registry
clinicaltrials.gov
Start Date
March 26, 2019
End Date
February 14, 2022
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

THEODOROU DIMITRIOS

PROFESSOR

University of Athens

Eligibility Criteria

Inclusion Criteria

  • patients with esophageal cancer
  • 18 years or older

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

infective complications

Time Frame: first six postoperative months

surgical site infection,pneumonia,intraabdominal sepsis,postoperative fever or other signs of sepsis

Secondary Outcomes

  • readmission rate(first six postoperative months)
  • anastomotic leak(first six postoperative months)
  • postoperative arrhythmia or other cardiac complications(first six postoperative months)
  • reoperation(first six postoperative months)
  • disease-associated death during the first six postoperative months(first six postoperative months)
  • length of hospital stay(first six postoperative months (including first admission and any other readmission))
  • length of stay in the ICU(first six postoperative months)

Study Sites (1)

Loading locations...

Similar Trials